Compare
Inhibikase Therapeutics, Inc. vs Editas Medicine, Inc. vs Caribou Biosciences, Inc. vs Sutro Biopharma, Inc.
| Latest fiscal year | Inhibikase Therapeutics, Inc. IKT | Editas Medicine, Inc. EDIT | Caribou Biosciences, Inc. CRBU | Sutro Biopharma, Inc. STRO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $40.52M | $11.16M | $102.48M |
| Revenue growth (YoY) | n/a | +25.4% | +11.7% | +65.2% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -394.9% | n/m | -154.5% |
| Net margin | n/a | -395.0% | n/m | -186.5% |
| Net income | -$48.26M | -$160.06M | -$148.12M | -$191.09M |
| EPS (Diluted) | -$0.49 | -$1.80 | -$1.59 | -$22.49 |
| Operating cash flow | -$27.79M | -$165.24M | -$110.99M | -$177.23M |
| Free cash flow | -$27.80M | -$165.85M | -$112.35M | n/a |
| Cash & equivalents | $178.80M | $146.65M | $12.36M | $58.13M |
| Total assets | $181.20M | $186.53M | $175.37M | $173.83M |
| Total liabilities | $8.30M | $159.25M | $53.19M | $306.28M |
| Shareholders' equity | $172.90M | $27.29M | $122.17M | -$132.45M |
| Return on year-end equity | -27.9% | -586.6% | -121.2% | n/a |
| Shares outstanding | 131.69M | 97.87M | 95.14M | 8.58M |
Revenue, most recent five fiscal years
| Fiscal year | Inhibikase Therapeutics, Inc. | Editas Medicine, Inc. | Caribou Biosciences, Inc. | Sutro Biopharma, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2024-12-31 | $40.52M Ended 2025-12-31 | $11.16M Ended 2025-12-31 | $102.48M Ended 2025-12-31 |
| 1 year earlier | $260.5K Ended 2023-12-31 | $32.31M Ended 2024-12-31 | $9.99M Ended 2024-12-31 | $62.04M Ended 2024-12-31 |
| 2 years earlier | $123.4K Ended 2022-12-31 | $78.12M Ended 2023-12-31 | $34.48M Ended 2023-12-31 | $153.73M Ended 2023-12-31 |
| 3 years earlier | $3.10M Ended 2021-12-31 | $19.71M Ended 2022-12-31 | $13.85M Ended 2022-12-31 | $67.77M Ended 2022-12-31 |
| 4 years earlier | $698.5K Ended 2020-12-31 | $25.54M Ended 2021-12-31 | $9.60M Ended 2021-12-31 | $61.88M Ended 2021-12-31 |